TO EVALUATE THE THERAPEUTIC EFFICACY OF â??POTTANAMâ?? AS EXTERNAL THERAPY and SIDDHA POLYHERBAL FORMULATION â??AAYIL PATTAI CHOORANAMâ?? (INTERNAL) IN THE TREATMENT OF â??CEGANA VATHAMâ?? (CERVICAL SPONDYLOSIS)

An Open labelled non randomised Phase II comparative clinical trail to evaluate the therapeutic efficacy of POTTANAM (External therapy) and AAYIL PATTAI CHOORANAM (Internal) for CEGANA VATHAM (Cervical Spondylosis)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/06/019936

Enrollment

Registered

2019-06-28

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M472- Other spondylosis with radiculopathy

Interventions

Intervention1: External therapy-Pottanam and Aayilpattai chooranam as internal medicine: External therapy-Pottanam and Aayilpattai chooranam- 2-3grms thrice a day for 48 days Control Intervention1: NI

Eligibility

Inclusion criteria

Inclusion criteria: Neck pain Radiating pain to the upper limbs With or without numbness in the upper limbs Giddiness and Neck Stiffness Patient who are willing for admission and stay in IPD or willing to attend OPD Patients who are Willing to give blood samples for laboratory investigations

Exclusion criteria

Exclusion criteria: Cervical rib Trauma Spina bifida Ankylosing spondylosis Tuberculosis in spine Cardiac disease • Other systemic illness

Design outcomes

Primary

Measure	Time frame
Comparison of change from baseline in Oswestry Neck Disability Index at day 48 between Group I and Group IITimepoint: 48 days	—

Secondary

Measure	Time frame
1.Assessment of safety parameters 2.Assessment of quality of life by EQ-5D 3.To evaluate the efficacy of the trial drugTimepoint: 48 days;Assessment of safety parameters Assessment of quality of life by EQ-5D Timepoint: GROUP I Intermittent external therapy 1st sitting 50% of symptoms will reduce 2nd sitting 80% of symptoms will reduce GROUP II after giving internal medicine and external therapy 50% of symptoms will reduce within 22 days 80% of symptoms will reduce within 48 days	—

Measure

Time frame

1.Assessment of safety parameters 2.Assessment of quality of life by EQ-5D 3.To evaluate the efficacy of the trial drugTimepoint: 48 days;Assessment of safety parameters Assessment of quality of life by EQ-5D Timepoint: GROUP I Intermittent external therapy 1st sitting 50% of symptoms will reduce 2nd sitting 80% of symptoms will reduce GROUP II after giving internal medicine and external therapy 50% of symptoms will reduce within 22 days 80% of symptoms will reduce within 48 days

—

Countries

India

Contacts

Public ContactBKaruppannan

Govt Siddha Medical College Hospital

dr.ahmed63@gmail.com9442542282

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026